SRDAN VERSTOVSEK to Cell Transformation, Neoplastic
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Cell Transformation, Neoplastic.
Connection Strength
1.296
-
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 06 01; 125(11):1855-1866.
Score: 0.347
-
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010 Jan 15; 70(2):447-52.
Score: 0.185
-
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009 Nov; 90(4):522-525.
Score: 0.180
-
Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol. 2017 May; 96(5):733-738.
Score: 0.076
-
Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S105-13.
Score: 0.073
-
Murine splenic macrophage tumoricidal activation by cytokines. Exp Hematol. 1995 Jun; 23(6):519-28.
Score: 0.067
-
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. 2014 Jan; 55(1):121-7.
Score: 0.058
-
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012 May 10; 119(19):4480-5.
Score: 0.054
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 01; 366(9):799-807.
Score: 0.053
-
Competing cell clones in myeloproliferative neoplasm. Blood. 2010 Dec 02; 116(23):5074-5.
Score: 0.049
-
Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer. 2004 Apr 15; 100(8):1578-89.
Score: 0.031
-
Bone marrow findings in blast phase of polycythemia vera. Ann Hematol. 2018 Mar; 97(3):425-434.
Score: 0.020
-
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 2017 01; 102(1):79-84.
Score: 0.018
-
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016 06; 101(6):660-71.
Score: 0.018
-
DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1969-73.
Score: 0.017
-
Significance of cytogenetic abnormalities in patients with polycythemia vera. Leuk Lymphoma. 2013 Dec; 54(12):2667-70.
Score: 0.014
-
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):315-318.e2.
Score: 0.014
-
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010 Apr; 16(4):555-9.
Score: 0.012
-
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007 Jun; 31(6):737-40.
Score: 0.009